Vodis Pharmaceuticals Inc (OTCMKTS:VDQSF) completed the first harvest from its Delta, British Colombia, based 12,000 Sq. Ft. indoor facility. The company planted 37 varieties on receiving the license from the Canada Revenue Agency and Health Canada in early 2020 to test the suitability of the conditions at this facility for proprietary cultivars. It is also to meet the evaluation criteria set by Health Canada. The company also uses this initial run to validate the nutrient delivery systems, operational processes, and lighting configuration.
Next crop harvest in mid-August
Vodis scheduled for the harvesting of the next crop that comprises three cultivars during mid-August 2020. The company, a small batch cannabis manufacturer, focuses on supplying unique products to Canada’s consumers. Most discerning Canadian cannabis consumers will get hand-harvested, dried, and trimmed flower products. The company also switches to an economically sustainable and environmentally friendly living soil to grow high-quality cannabis. Vodis’s customers will benefit from flavorable terpenes from cannabis grown in living soil compared to the varieties cultivated through other methods.
After entering the human body, terpenes influences several internal functions. Terpenes show a significant impact on endocrine, endocannabinoid, and neuroendocrine system. They comprise several isoprene units. Two isoprenes are combined to create monoterpenes such as thujene, sabinene, neral, alpha-pinene, and fenchone. Alpha-pinenes safeguards organs and boosts memory.
Improved revenues from Delta facility
To enhance the revenues from its Delta facility, Vodis evaluates its processing options and co-packaging methods in alliance with other partners. It is also taking the help and knowledge of experienced leaders in the industry for streamlining its processes.
Applies for Dealer’s license
Vodis is applying for a dealer license to use the level 8 vault for processing, distributing, and selling the psychedelic substances and supporting the surging psychedelics.
The market for psychedelic drugs
Psychedelics are gaining popularity because they can cure mental disorders and depression. They will play a vital role in improving energy levels and alter sensory perceptions. Psychedelics are classified into serotonergic, empathogens, and dissociative drugs. The demand for psychedelic drugs is expected to reach $6.86 billion by 2027 growing at CAGR of 16.3% between 2020 and 2027.